<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author><author><style face="normal" font="default" size="100%">Tsatalas, C.</style></author><author><style face="normal" font="default" size="100%">Zomas, A.</style></author><author><style face="normal" font="default" size="100%">Hamilos, G.</style></author><author><style face="normal" font="default" size="100%">Panayiotidis, P.</style></author><author><style face="normal" font="default" size="100%">Margaritis, D.</style></author><author><style face="normal" font="default" size="100%">Matsouka, C.</style></author><author><style face="normal" font="default" size="100%">Economopoulos, T.</style></author><author><style face="normal" font="default" size="100%">Anagnostopoulos, N.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone</style></title><secondary-title><style face="normal" font="default" size="100%">Seminars in Oncology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2003</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2003</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-0037397379&amp;doi=10.1053%2fsonc.2003.50079&amp;partnerID=40&amp;md5=bec3f34f2d55a00032d51bcf8e7989ce</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">30</style></volume><pages><style face="normal" font="default" size="100%">265 - 269</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">To evaluate the activity of thalidomide in Waldenstrom's macroglobulinemia (WM), 20 patients were treated on a dose schedule that escalated from 200 mg/d to 600 mg/d. On an intention-to-treat basis, five (25%) patients achieved a partial response, which was noted within 3 months of treatment. Adverse effects were common and prevented dose escalation of thalidomide in 75% of patients and led to premature discontinuation of treatment in 35%. We subsequently evaluated the oral combination of clarithromycin (500 mg twice per day), low-dose thalidomide (200 mg once daily), and dexamethasone (40 mg once per week). Our preliminary analysis on 12 previously treated patients indicate activity of this regimen in WM: three patients achieved a partial response and two patients demonstrated monoclonal protein reduction of greater than 25%. This combination was associated with a variety of side effects due not only to thalidomide, but also to corticosteroids and to clarithromycin. Our preliminary data indicate that this combination may be a useful salvage regimen for some patients with heavily pretreated macroglobulinemia. © 2003 Elsevier Inc. All rights reserved.</style></abstract><issue><style face="normal" font="default" size="100%">2</style></issue><notes><style face="normal" font="default" size="100%">Cited By :51Export Date: 21 February 2017</style></notes></record></records></xml>